Cybin D/B/A Helus Pharma (HELP.NE)
Cboe CA · CAD · Healthcare · Biotechnology
CA$14.43 (+0.77%) as of
Key statistics
- Market cap
- 1.05B
- Forward P/E
- -5.84
- EPS (TTM)
- -5.70
- Dividend yield
- 0.00%
- 52-week range
- 5.30 – 20.88
- Beta
- 0.54
- Profit margin
- 0.00%
- Volume
- 7.72k
About Cybin D/B/A Helus Pharma
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Toronto, ON, Canada
- Employees
- 100
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.